Balaxi Pharmaceuticals Ltd
BALAXI
Company Profile
Business description
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
Contact
Phase-III, Road No: 81, Jubilee Hills
Plot No.409, H,No: 8-2-293
MAPS Towers, 3rd Floor
HyderabadTG500 096
INDT: +91 4023555300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
48
Stocks News & Analysis
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
stocks
For US software stocks, it’s been an AI bust, not a boom
Once-hot software names are lagging. Are they good buys?
stocks
Finding value in the Aussie mining sector
Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,799.70 | 43.70 | -0.49% |
| CAC 40 | 7,959.67 | 22.98 | -0.29% |
| DAX 40 | 23,239.18 | 147.31 | 0.64% |
| Dow JONES (US) | 46,448.27 | 202.86 | 0.44% |
| FTSE 100 | 9,534.91 | 4.80 | -0.05% |
| HKSE | 25,875.36 | 158.86 | 0.62% |
| NASDAQ | 22,872.01 | 598.92 | 2.69% |
| Nikkei 225 | 48,655.31 | 29.43 | 0.06% |
| NZX 50 Index | 13,480.43 | 19.42 | -0.14% |
| S&P 500 | 6,705.12 | 102.13 | 1.55% |
| S&P/ASX 200 | 8,512.30 | 51.40 | -0.60% |
| SSE Composite Index | 3,880.22 | 43.45 | 1.13% |